2-(5-噁唑基)苯胺 | 774238-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(5-噁唑基)苯胺
• 中文别名: 2-(1,3-恶唑-5-基)苯胺
• 英文名称: 2-(oxazol-5-yl)aniline
• 英文别名: 2-(Oxazol-5-yl)phenylamine；2-oxazol-5-ylphenylamine；2-(1,3-Oxazol-5-yl)aniline
• CAS: 774238-36-7
• 化学式: C₉H₈N₂O
• mdl: MFCD07772822
• 分子量: 160.175
• InChiKey: UZPQWOKKMYUKNI-UHFFFAOYSA-N

物化性质

• 熔点：
  54 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(1,3-Oxazol-5-yl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(1,3-Oxazol-5-yl)aniline
CAS number: 774238-36-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O
Molecular weight: 160.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(5-噁唑基)苯胺 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 、 氢氧化钾 作用下， 以 水 为溶剂， 反应 1.5h， 生成 5-(2-hydrazinylphenyl)oxazole
  参考文献：
  名称：

  EP1612204

  摘要：

  公开号：
• 作为产物：
  描述：

  5-(2-硝基苯基)-1,3-噁唑 在 盐酸 、 铁粉 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 以68%的产率得到2-(5-噁唑基)苯胺
  参考文献：
  名称：

  通过在恶唑的C-4位直接反应 合成4-取代的恶唑并[4,5- c ]喹啉†

  摘要：

  通过改进的Pictet-Spengler方法并使用Cu（TFA）2作为催化剂，已经描述了一种易于合成4-芳基取代的恶唑并[4,5- c ]喹啉的方法。在存在更高反应性的C-2位置的情况下，开发的方法无需任何预官能化即可直接将恶唑的C-4位置官能化。所建立方法的多功能性已通过其在合成4-取代的唑并-[1,8]萘啶环体系中的应用得到证实。

  DOI：

  10.1039/c4ob02224f

文献信息

• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130225589A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)化合物或药理可接受的盐，其中R1、R2、R3、R4和B在描述中定义。本发明还涉及包含所述化合物的组合物，这些化合物可用于抑制诸如wee-1的激酶，以及治疗诸如癌症疾病的方法。
• Lead identification and structure–activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists
  作者：Afjal H. Miah、Royston C. B. Copley、Daniel O'Flynn、Jonathan M. Percy、Panayiotis A. Procopiou

  DOI：10.1039/c3ob42443j

  日期：——

  A knowledge-based library of aryl 2,3-dichlorophenylsulfonamides was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. X-ray diffraction studies were used to identify the pyrazole ring as a moiety that could bring about intramolecular hydrogen bonding with the sulfonamide NH and provide a clip or orthogonal conformation that was believed to be the preferred active conformation. Replacement of the core phenyl ring with a pyridine, and replacement of the 2,3-dichlorobenzenesulfonamide with 5-chlorothiophenesulfonamide provided compound 33 which has excellent physicochemical properties and represents a good starting point for a lead optimisation programme. Electronic structure calculations indicated that the preference for the clip or orthogonal conformation found in the small molecule crystal structures of 7 and 14 was in agreement with the order of potency in the biological assay.

  基于知识的芳基2,3-二氯苯磺酰胺类化合物库被合成并筛选为人CCR4拮抗剂，旨在确定一个适合作为先导优化计划起点的候选化合物。X射线衍射研究用于鉴定吡唑环为一个可以通过分子内氢键与磺酰胺NH结合并提供被认为是优选活性构象的夹子或正交构象的基团。用吡啶替换核心苯环，并用5-氯噻吩磺酰胺替换2,3-二氯苯磺酰胺得到了化合物33，其具有优异的物化性质，并代表了一个良好的先导优化计划起点。电子结构计算表明，小分子晶体结构中发现的夹子或正交构象的偏好与生物测定中的效力顺序一致。
• α1-Adrenoceptor activation: A comparison of 4-(Anilinomethyl)imidazoles and 4-(Phenoxymethyl)imidazoles to related 2-imidazolines
  作者：Stephen J Hodson、Eric C Bigham、Deanna T Garrison、Michael J Gobel、Paul E Irving、James A Liacos、Frank Navas, III、David L Saussy、Bryan W Sherman、Jason D Speake、Michael J Bishop

  DOI：10.1016/s0960-894x(02)00753-9

  日期：2002.12

  found in adrenergic receptor ligands is responsible for the disruption. Novel 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles are agonists of the cloned human alpha(1)-adrenoceptors in vitro, and potent, selective alpha(1A)-adrenoceptor agonists have been identified in this series. These imidazoles demonstrate similar potencies and alpha(1)-subtype selectivities as the corresponding 2-substituted

  文献报道表明，螺旋间盐桥的破坏对于α（1）-肾上腺素受体激活至关重要，而肾上腺素能受体配体中发现的碱性胺是造成这种破坏的原因。新型的4-（苯胺基甲基）咪唑和4-（苯氧基甲基）咪唑是体外克隆的人α（1）-肾上腺素受体激动剂，并且在该系列中已鉴定出有效的选择性α（1A）-肾上腺素受体激动剂。这些咪唑显示出与相应的2-取代的咪唑啉相似的效价和alpha（1）-亚型选择性。SAR值非常接近，表明尽管碱性存在很大差异，但这些咪唑和咪唑啉可能建立相同的相互作用来激活α（1）-肾上腺素受体。
• Hydrazone derivative
  申请人：Kawagoe Keiichi

  公开号：US20060276433A1

  公开（公告）日：2006-12-07

  A compound represented by the following formula (I): wherein R 1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R 2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R 3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof.

  以下是式子（I）所代表的化合物： 其中，R1代表氢、芳基（可能带有取代基）、饱和或不饱和的5-至7-成员杂环基（可能带有取代基）等； R2代表氢、芳基（可能带有取代基）、饱和或不饱和的5-至7-成员杂环基（可能带有取代基）等； R3代表氢等； Ar代表从芳香族碳氢化合物衍生的二价基团等； X代表单键、线性或支链烷基，具有1至3个碳原子，可能带有取代基等； G代表卤素、饱和或不饱和的5-或6-成员环烃基（可能带有取代基）、饱和或不饱和的5-至7-成员杂环基（可能带有取代基）等，其盐或溶剂化物；以及用于抑制淀粉样蛋白或类淀粉样蛋白的聚集和/或沉积的药剂，包括该化合物、其盐或溶剂化物。
• Compounds Useful for Inhibiting Chk1
  申请人：Gaudino John Joseph

  公开号：US20080214573A1

  公开（公告）日：2008-09-04

  Substituted urea compounds useful in the treatment of diseases and C 1-3 alkyleneOR 3 conditions related to DNA damage or lesions in DNA replication are disclosed formula (I), wherein X 1 is null, —O—, —S—, —CH 2 —, or —N(R 1 )—; X 2 is —O—,. -£>.-, or —N(R 1 )—, -.. Y xs 0 or S; or =y represents two hydrogen atoms attached to a common carbon atom, —W is selected from the group consisting or heteroaryl, aryl, heterocycloalkyl, cycloalkyl, and C1-6 alkyl substituted with a heteroaryl, or aryl group; R 6 is —C≡C—R 7 or heteroaryl; R 8 , R 9 , and R 10 , independently, are selected from the group consisting of halo, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, OCP 3 , CF 3 , NO 2 , CN, NC, N(R 3 ) 2 , OR 3 , CO 2 R 3 , C(O)N (R 3 ) 2 , C(O)R 3 , N(R 1 )COR 3 , N(R 1 )C(O)OR 3 , N(R 8 )C(O)OR 3 , N(R 1 )C(O)C 1-3 alkyleneC(O)R 3 , N(R 1 )C(O)C 1-3 alkyleneC(O)OR 3 , N(R 1 )C(O)C 1-3 alkyleneOR 3 , N(R 1 )C(O)C 1-3 alkyleneNHC(O)OR 3 , N(R 1 )C(O)C 1-3 alkyleneSO 2 , NR 3 , C 1-3 alkyleneOR 3 , and SR 3 ; Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed

  本文披露了一种在治疗与DNA损伤或DNA复制中的损伤有关的疾病和C1-3烷基OR3条件下有用的替代脲化合物，其化学式为(I)，其中X1为null、—O—、—S—、—CH2—或—N(R1)—；X2为—O—、—、或—N(R1)—；Y为0或S；或=y表示连接到共同碳原子上的两个氢原子；W选自由杂环、芳香族、杂环烷基、环烷基和C1-6烷基，其中取代为杂环或芳基基团；R6为—C≡C—R7或杂环；R8、R9和R10独立地选自卤素、可选取代的C1-6烷基、C2-6烯基、C2-6炔基、OCP3、CF3、NO2、CN、NC、N(R3)2、OR3、CO2R3、C(O)N(R3)2、C(O)R3、N(R1)COR3、N(R1)C(O)OR3、N(R8)C(O)OR3、N(R1)C(O)C1-3烷基C(O)R3、N(R1)C(O)C1-3烷基C(O)OR3、N(R1)C(O)C1-3烷基OR3、N(R1)C(O)C1-3烷基NHC(O)OR3、N(R1)C(O)C1-3烷基SO2、NR3、C1-3烷基OR3和SR3；还披露了制备该化合物的方法以及其作为治疗剂的用途，例如在治疗癌症和其他由DNA复制缺陷、染色体分离或细胞分裂引起的疾病中使用。